Notably, we discovered a unifying impairment in degrading Miro1 at 6 h after CCCP treatment in 25 PD (83.3%) and 36 Risk (genetic carriers) lines (85.7%; Figure 1C and Supplementary Table 1). This evidence concerns the gene RHOT1 and Parkinson disease.